How many insider trades does FilingIQ track for PHAT?

FilingIQ tracks 293 Form 4 insider transactions for PHAT (Phathom Pharmaceuticals, Inc.), covering filings from Oct 30, 2019 onwards. 2 of those are dated within the last 90 days.

Are PHAT insiders net buyers or net sellers?

Across the full Form 4 history for PHAT, 30 transactions (10%) were open-market purchases and 166 (57%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does PHAT insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is PHAT in?

Phathom Pharmaceuticals, Inc. (PHAT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $950.98M.

PHAT insider trading

Healthcare

Phathom Pharmaceuticals, Inc.: insider trade history from SEC Form 4 filings.

Total Form 4 trades

293

Last 90 days

Buys / sells

10% / 57%

Market cap

$950.98M

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Company website: www.phathompharma.com

PHAT insider activity at a glance

FilingIQ tracks 293 insider transactions for PHAT in filings since Oct 30, 2019. The most recent transaction is dated Sep 3, 2026.

Across the full history, 30 open-market purchases and 166 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on PHAT insider trades is 55.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live PHAT trades on FilingIQ Raw filings on SEC EDGAR

Latest PHAT Form 4 filings

Breedlove Robert Charles Principal Accounting Officer

F Sep 8, 2026

Breedlove Robert Charles Principal Accounting Officer

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 820

UNITED THERAPEUTICS Corp

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

CORT 110

CORCEPT THERAPEUTICS INC

TEM 104

Tempus AI, Inc.

Frequently asked

How many insider trades does FilingIQ track for PHAT?: FilingIQ tracks 293 Form 4 insider transactions for PHAT (Phathom Pharmaceuticals, Inc.), covering filings from Oct 30, 2019 onwards. 2 of those are dated within the last 90 days.
Are PHAT insiders net buyers or net sellers?: Across the full Form 4 history for PHAT, 30 transactions (10%) were open-market purchases and 166 (57%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does PHAT insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is PHAT in?: Phathom Pharmaceuticals, Inc. (PHAT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $950.98M.

Methodology & sources

Every PHAT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.